The global brain tumor drugs industry is projected to expand at a 9.2% CAGR from 2023 to 2033. In 2023 and 2033, respectively, the market value is projected to reach US$ 2.65 billion and US$ 6.30 billion. Utilising nanoparticles, drugs are delivered in combination directly to cancer cells or tumors. Additionally, this technique has led to a decrease in medication dosage, an extension of the shelf life, and a decrease in toxicity. The blood-brain barrier, which has been a significant barrier in the treatment of brain tumors, has been proved to be successfully crossed by a small number of nanodrugs.
The market for pharmaceuticals used to treat brain tumors is known as the ” global brain tumor drugs industry,” and it is a subset of the pharmaceutical business. Brain tumors are abnormal cell growths in the brain that may or may not be cancerous (benign) or malignant (cancerous). They can have a variety of symptoms and be fatal.
Get Recently Updated Report of Market as Sample Copy! https://www.futuremarketinsights.com/reports/sample/rep-gb-16725
In recent years, there have been substantial developments and breakthroughs in the field of brain tumor medications, with the goal of enhancing patient outcomes and extending survival times. Chemotherapy, radiation therapy, and surgery are frequently used to treat brain tumors. Drug therapy, however, are essential for controlling brain tumors, especially for those that cannot be surgically removed or in situations where tumors recur.
A brain tumor is an abnormal mass of tissue in which the growth and division of brain cells occurs rapidly and uncontrollably. Primary brain tumors and metastatic brain tumors are the two categories into which brain cancers are divided. Primary brain tumors are those that develop from the tissues of the brain or the tissues around the brain. Pharmaceutical companies have improved supply chain management, which has led to more investment in R&D, manufacturing quality assurance, and research and development.
Key Takeaways:
- The brain tumor drugs market is expected to record a CAGR of 9.2% during the forecast period 2023 to 2033.
- The primary drivers of the market are an increase in brain cancer prevalence, the presence of promising pipeline candidates, and an increased need for precision and customized treatment to drive market expansion.
- North America dominated the brain tumor drugs market.
In Case Of Any Queries, Don’t Hesitate To Contact Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16725
Key Development in the Brain Tumor Drugs Market:
- April 2021 – MindMed and Nextage Therapeutics signed a Memorandum of Understanding (MOU) to maximize the administration of selected psychedelic drug candidates using Nextage’s unique Brain Targeting Liposome System (BTLS) delivery technology.
- March 2021 – Roche and GenMark Diagnostics signed a comprehensive merger agreement for Roche to entirely acquire GenMark for US$ 24.05 per share in an all-cash transaction.
- September 2022 – F. Hoffmann-La Roche Ltd. announced an agreement to acquire Good Therapeutics. With this acquisition, the firm gains access to Good Therapeutic’s platform technology, which is relevant to a wide range of sectors such as cancer, autoimmune illnesses, metabolic disease, and pain management.
- June 2022 – Novartis AG received the United States FDA approval for Tafinlar + Mekinist for the treatment of paediatric and adult patients with solid cancers containing the BRAF V600E mutation. BRAF mutations are responsible for tumor growth in over 20 different tumor types, including brain, thyroid, and others.
- November 2021 – Pfizer Inc. purchased Trillium Therapeutics, a clinical-stage immuno-oncology startup focused on creating novel cancer medicines.
Customize Your Report: Tailor the Exclusive Insights to Your Brain Tumor Drug Market Strategy! https://www.futuremarketinsights.com/customization-available/rep-gb-16725
Competitive Landscape:
Prominent Participants in the Market
- AstraZeneca plc
- Johnson & Johnson Inc
- Merck & Co
- Pfizer Inc
- Hoffmann-La Roche Ltd
- Y-mAbs Therapeutics, Inc
- Shimadzu Corporation
- Bristol-Myers Squibb
- Bayer AG
- Reddy’s Laboratories Ltd
- Among others
Key Segment:
By Therapy:
- Targeted Therapy
- Chemotherapy
- Immunotherapy
- Others
By Indication:
- Pituitary
- Meningioma
- Glioma
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail & Online Pharmacy
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- The Middle East and Africa
Gain Immediate Access to Detailed Market Insights: Purchase Now! https://www.futuremarketinsights.com/checkout/16725
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
